The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Dristhi Ragoonanan; Irtiza N. Sheikh; Sumit Gupta; Sajad J. Khazal; Priti Tewari; Demetrios Petropoulos; Shulin Li; Kris M. Mahadeo

doi:10.3390/biomedicines10092286

Biomedicines (Sep 2022)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Dristhi Ragoonanan,
Irtiza N. Sheikh,
Sumit Gupta,
Sajad J. Khazal,
Priti Tewari,
Demetrios Petropoulos,
Shulin Li,
Kris M. Mahadeo

Affiliations

Dristhi Ragoonanan: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Irtiza N. Sheikh: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Sumit Gupta: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Sajad J. Khazal: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Priti Tewari: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Demetrios Petropoulos: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Shulin Li: Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Kris M. Mahadeo: Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

DOI: https://doi.org/10.3390/biomedicines10092286
Journal volume & issue: Vol. 10, no. 9
p. 2286

Abstract

Read online

Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.

Published in Biomedicines

ISSN: 2227-9059 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: http://www.mdpi.com/journal/biomedicines

About the journal

Abstract

Keywords